The treatment of severe intra-abdominal infections: the role of piperacillin/tazobactam.
Intensive Care Med
; 20 Suppl 3: S35-8, 1994 Jul.
Article
in En
| MEDLINE
| ID: mdl-7962987
ABSTRACT
Intra-abdominal infections require treatment effective against both aerobic and anaerobic bacteria. Piperacillin/tazobactam, a beta-lactam/beta-lactamase-inhibitor combination, has a spectrum that includes Gram-positive and Gram-negative aerobic and anaerobic organisms. In one comparative study of piperacillin/tazobactam and gentamicin/clindamycin, 88% of patients treated with piperacillin/tazobactam had a favorable clinical outcome at endpoint compared to 74% of patients treated with gentamicin plus clindamycin. Bacteriological response at endpoint was 87% in the piperacillin/tazobactam group and 74% in the gentamicin plus clindamycin group. In a comparative trial of piperacillin/tazobactam versus imipenem/cilastatin, the clinical cure rate was 91% in the piperacillin/tazobactam group and 69% in the imipenem/cilastatin group (p = 0.005). Among microbiologically evaluable patients, the infecting organism was eradicated in 93% of piperacillin/tazobactam-treated patients compared to 76% eradication among imipenem/cilastatin-treated patients (p = 0.029). Results of these clinical trials and others have shown that piperacillin/tazobactam is a safe and effective alternative to either combination or monotherapy for intra-abdominal infections.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Piperacillin
/
Bacterial Infections
/
Penicillanic Acid
/
Beta-Lactamase Inhibitors
Limits:
Humans
Language:
En
Journal:
Intensive Care Med
Year:
1994
Type:
Article
Affiliation country:
Sweden